Low-dose interleukin-2 therapy: A driver of an imbalance between immune tolerance and autoimmunity

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18574-18592

  Kosmaczewska, Agata ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Autoimmunity; Clinical trial; Immune tolerance; Immune mediated disease; Immunotherapy; Interleukin 2

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; JANUS KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 6; STAT PROTEIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DOWN REGULATION; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; VASCULITIS; ANIMAL; AUTOIMMUNE DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84908072047     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018574     Document Type: Review

References (96)

1. Gupta, S.; Cerosaletti, K.; Long, A. Renegade homeostatic cytokine responses in T1D: Drivers of regulatory/effector T cell imbalance. Clin. Immunol. 2014, 151, 146-154.
2. Wing, K.; Sakaguchi, S. Regulatory T cells exert checks and balances of self tolerance and autoimmunity. Nat. Immunol. 2010, 11, 7-13.
3. Dendrou, C. A.; Wicker, L. S. The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice. J. Clin. Immunol. 2008, 6, 685-696.
4. Sgouroudis, E.; Albanse, A.; Piccirillo, C. A. Impact of protective IL-2 allelic variants on CD4+Foxp3+ regulatory T cell function in situ and resistance to autoimmune diabetes in NOD mice. J. Immunol. 2008, 181, 6283-6292.
5. Tang, Q.; Adams, J. Y.; Penaranda, C.; Melli, K.; Piaggio, E.; Sgouroudis, E.; Piccirillo, C. A.; Salomon, B. L.; Bluestone, J. A. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28, 687-697.
6. Yamanouchi, D.; Rainbow, D.; Serra, P.; Howlett, K.; Hunter, K.; Garner, V. E.; Gonzalez-Munoz, A.; Clark, J.; Veijola, R.; Veijola, R.; et al. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 2007, 39, 329-337.
7. Setoguchi, R.; Hori, S.; Takahashi, T.; Sakaguchi, S. Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005, 201, 723-735.
8. high T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 2009, 4, e6527.
9. Long, S. A.; Rieck, M.; Sanda, S.; Bollyky, J. B.; Samuels, P. L.; Goland, R.; Ahmann, A.; Rabinovitch, A.; Aggarwal, S.; Phippard, D.; et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Treg yet transiently impairs beta-cell function. Diabetes 2012, 61, 2340-2348.
10. Altman, A.; Theofilopoulos, A. N.; Weiner, R.; Katz, D. H.; Dixon, F. J. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J. Exp. Med. 1981, 154, 791-808.
11. Huang, F. P.; Stott, D. I. Restoration of an early, progressive defect in responsiveness to T cell activation in lupus mice by exogenous IL-2. Autoimmunity 1993, 15, 19-29.
12. Brunkow, M. E.; Jeffery, E. W.; Hjerrild, K. A.; Paeper, B.; Clark, L. B.; Yasako, S. A.; Wilkinson, J. E.; Galas, D.; Ziegler, S. F.; Ramsdell, F. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27, 337-342.
13. Hakonarson, H.; Qu, H. Q.; Bradfield, J. P.; Marchand, L.; Kim, C. E.; Glessner, J. T.; Grabs, R.; Casalunovo, T.; Taback, S. P.; Frackelton, E. C.; et al. A novel susceptibility locus for type 1 diabetes on Chr12q13 identified by a genome-wide association study. Diabetes 2008, 57, 1143-1146.
14. Ochs, H. D.; Gambineri, E.; Torgerson, T. R. IPEX, FOXP3 and regulatory T cells: A model for autoimmunity. Immunol. Res. 2007, 38, 112-121.
15. Rosenberg, S. A.; Lotze, M. T.; Muul, L. M.; Leitman, S.; Chang, A. E.; Ettinghausen, S. E.; Matory, Y. L.; Skibber, J. M.; Shiloni, E.; Vetto, J. T.; et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313, 1485-1492.
16. Kosmaczewska, A.; Swierkot, J.; Ciszak, L.; Szteblich, A.; Chrobak, A.; Karabon, L.; Partyka, A.; Szechinski, J.; Wiland, P.; Frydecka, I. Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement. Rheumatol. Int. 2014, 34, 243-253.
17. Goldstein, J. D.; Perol, L.; Zaragoza, B.; Baeyens, A.; Marodon, G.; Piaggio, E. Role of cytokines in thymus-vs. peripherally derived-regulatory T cell differentiation and function. Front. Immunol. 2013, 4, doi: 10. 3389/fimmu. 2013-00155.
18. Baeyens, A.; Perol, L.; Fourcade, G.; Cagnard, N.; Carpentier, W.; Woytschak, J.; Boyman, O.; Hartemann, A.; Piaggio, E. Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes. Diabetes 2013, 62, 3120-3131.
19. Wilson, M. S.; Pesce, J. T.; Ramalingam, T. R.; Thompson, R. W.; Cheever, A.; Wynn, T. A. Suppression of murine allergic airway disease by IL-2; anti-IL-2 monoclonal antibody-induced regulatory T cells. J. Immunol. 2008, 181, 6942-6954.
20. Webster, K. E.; Walters, S.; Kohler, R.; Mrkvan, T.; Boyman, O.; Surh, C. D.; Grey, S. T.; Sprent, J. In vivo expansion of Treg cells with IL-2 mAb complexes; induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 2009, 206, 751-760.
21. Grinberg-Bleyer, Y.; Baeyens, A.; You, S.; Elhage, R.; Fourcade, G.; Gregoire, S.; Cagnard, N.; Carpentier, W.; Tang, Q.; Bluestone, J.; et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 2010, 207, 1871-1878.
22. Dinh, T. N.; Kyaw, T. S.; Kanellakis, P.; To, K.; Tipping, P.; Toh, B. H.; Bobik, A.; Agrotis, A. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation 2012, 126, 1256-1266.
23. Koreth, J.; Matsuoka, K.; Kim, H. T.; McDonough, S. M.; Bindra, B.; Alyea, E. P., 3rd; Armand, P.; Cutler, C.; Ho, V. T.; Treister, N. S.; et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365, 2055-2066.
24. Matsuoka, K.; Koreth, J.; Kim, H. T.; Bascug, G.; McDonough, S.; Kawano, Y.; Murase, K.; Cutler, C.; Ho, V. T.; Alyea, E. P.; et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci. Transl. Med. 2013, 5, doi: 10. 1126/scitranslmed. 3005265.
25. Saadoun, D.; Rosenzwajg, M.; Joly, F.; Six, A.; Carrat, F.; Thibault, V.; Sene, D.; Cacoub, P.; Klatzmann, D. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 2011, 365, 2067-2077.
26. Hartemann, A.; Bensimon, G.; Payan, C.; Jacqueminet, S.; Bourran, O.; Nicolas, N.; Fonfrede, M.; Rosenzwajg, M.; Bernard, C.; Klatzmann, D. Low-dose interleukin 2 in patients with type 1 diabetes: A phase 1/2 randomized, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013, 1, 295-305.
27. O'Gorman, W. E.; Dooms, H.; Thorne, S. H.; Kuswanto, W. F.; Simonds, E. F.; Krutzik, P. O.; Nolan, G. P.; Abbas, A. K. The initial phase of an immune response functions to activate regulatory T cells. J. Immunol. 2009, 183, 332-339.
28. + regulatory T cells. J. Immunol. 2007, 178, 280-290.
29. Fontenot, J. D.; Rasmussen, J. P.; Gavin, M. A.; Rudensky, A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 2005, 6, 1142-1151.
30. + regulatory T cells and for expansion of these cells. J. Immunol. 2007, 178, 2018-2027.
31. Passerini, L.; Allan, S. E.; Battaglia, M.; di Nunzio, S.; Alstad, A. N.; Levings, M. K; Roncarolo, M. G.; Bacchetta, R. STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+. Int. Immunol. 2008, 20, 421-431.
32. Zorn, E.; Nelson, E. A.; Mohseni, M.; Porcheray, F.; Kim, H.; Litsa, D.; Bellucci, R.; Raderschall, E.; Canning, C.; Soiffer, R. J.; et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108, 1571-1579.
33. Yang, C. H.; Tian, L.; Ling, G. S.; Trendell-Smith, N. J.; Ma, L.; Lo, C. K.; Stott, D. I.; Liew, F. Y.; Huang, F. P. Immunological mechanisms and clinical implications of regulatory T cell deficiency in a suystemic autoimmune disorder: Roles of IL-2 vs. IL-15. Eur. J. Immunol. 2008, 38, 1664-1676.
34. Brusko, T. M.; Wasserfall, C. H.; Clare-Salzler, M. J.; Schatz, D. A.; Atkinson, M. A. Functional defects and the influence of age on the frequency of CD4+CD25+ T cells in type 1 diabetes. Diabetes 2005, 54, 1407-1414.
35. Boyer, O.; Saadoun, D.; Abriol, J.; Dodille, M.; Piette, J. C.; Cacoub, P.; Klatzmann, D. CD4+CD25+ regulatory T cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. Blood 2004, 103, 3428-3430.
36. Xing, Q.; Wang, B.; Su, H.; Cui, J.; Li, J. Elevated Th17 cells are accompanied by FoxP3Treg cell decrease in patients with lupus nephritis. Rheumatol. Int. 2012, 32, 949-958.
37. Yang, J.; Chu, Y.; Yang, X.; Gao, D.; Zhu, L.; Yang, X.; Wan, L.; Li, M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheumatol. 2009, 60, 1472-1483.
38. Szmyrka-Kaczmarek, M.; Kosmaczewska, A.; Ciszak, L.; Szteblich, A.; Wiland, P. Peripheral blood Th17/Treg imbalance in patients with low-active systemic lupus erythematosus. Postepy Hig. Med. Dosw. 2014, 68, 893-898.
39. Landau, D. A.; Rosenzwajg, M.; Saadoun, D.; Trebeden-Negre, H.; Klatzmann, D.; Cacoub, P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheumatol. 2008, 58, 2897-2907.
40. Kawashima, M.; Miossec, P. mRNA quantification of T-bet, GATA-3, IFN-γ, and IL-4 shows a defectiva Th1 immune response in the peripheral blood from rheumatoid arthritis patients: Link with disease activity. J. Clin. Immunol. 2005, 25, 209-214.
41. Van Roon, J. A. G.; Verhoef, C. M.; van Roy J. L. A. M.; Gmelig-Meyling, F. H.; Huber-Bruning, O.; Lafeber, F. P.; Bijlsma, J. W. Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease. Ann. Rheum. Dis. 1997, 56, 656-660.
42. Sgouroudis, E.; Kornete, M.; Piccirillo, C. A. IL-2 production by dendritic cells promotes Foxp3+ regulatory T-cell expansion in autoimmune resistant NOD congenic mice. Autoimmunity 2011, 44, 406-414.
43. Zhang, H.; Chua, K. S.; Guimond, M.; Kapoor, V.; Brown, M. V.; Fleisher, T. A.; Long, L. M.; Bernstein, D.; Hill, B. J.; Douek, D. C.; et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 2005, 11, 1238-1243.
44. Kosmaczewska, A.; Ciszak, L.; Swierkot, J.; Szteblich, A.; Kosciow, K.; Frydecka, I. Exogenous IL-2 controls the balance in Th1, Th17, and Treg cell distribution in patients with progressive arthritis treated with TNF-alpha inhibitors. Inflammation 2014, doi: 10. 1007/s10753-014-9987-x.
45. Sadlack, B.; Lohler, J.; Schorle, H.; Klebb, G.; Haber, H.; Sickel, E.; Noelle, R. J.; Horak, I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 1995, 25, 3053-3059.
46. Suzuki, H.; Kundig, T. M.; Furlonger, C.; Wakeham, A.; Timms, E.; Matsuyama, T.; Schmits, R.; Simard, J. J.; Ohashi, P. S.; Greisser, H.; et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268, 1472-1476.
47. Willeford, D. M.; Chen, J.; Ferry, J. A.; Davidson, L.; Ma, A.; Alt, F. W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995, 3, 521-530.
48. + T regulatory cells in human autoimmunity: More than a numbers game. J. Immunol. 2011, 187, 2061-2066.
49. Garg, G.; Tyler, J. R.; Yang, J. H.; Cutler, A. J.; Downes, K.; Pekalski, M.; Bell, G. L.; Nutland, S.; Peakman, M.; Todd, J. A.; et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J. Immunol. 2012, 188, 4644-4653.
50. + T cells. Genes Immun. 2011, 12, 116-125.
51. Long, S. A.; Rieck, M.; Sanda, S.; Bollyky, M.; Tatum, M.; Shilling, H.; Zhang, S.; Zhang, Z. Y.; Pihoker, C.; Sanda, S.; et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4+CD25+ regulatory T cells of type 1 diabetic subjects. Diabetes 2010, 59, 407-415.
52. Marwaha, A. K.; Crome, S. Q.; Panagiotopoulos, C.; Berg, K. B.; Qin, H.; Quyang, Q.; Xu, L.; Priatel, J. J.; Levings, M. K.; Tan, R. Cutting edge: Increased IL-17-secreting T cells in children with new-onset type 1 diabetes. J. Immunol. 2010, 185, 3814-3818.
53. hi T cells of type 1 diabetic and multiple sclerosis patients. PLoS One 2014, 8, e83811.
54. Dendrou, C. A.; Plagnol, V.; Fung, E.; Yang, J. H.; Downes, K.; Cooper, J. D.; Nutland, S.; Coleman, G.; Himsworth, M.; Hardy, M.; et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 2009, 41, 1011-1015.
55. Long, A.; Buckner, J. H. Intersection between genetic polymorphisms and immune deviation in type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 2013, 20, 285-291.
56. + T cells with limited suppressor activity. Eur. J. Immunol. 2011, 41, 1480-1490.
57. Johnson, M. C.; Garland, A. L.; Nickolson, S. C.; Li, C.; Samulski, R. J.; Wang, B.; Tisch, R. Beta-cell-specific IL-2 therapy increases islet Foxp3+ Treg and suppresses type 1 diabetes in NOD mice. Diabetes 2013, 62, 3775-3784.
58. Crotty, S. Follicular helper T cells (TFH). Annu. Rev. Immunol. 2011, 29, 621-663.
59. Nurieva, R. I.; Chung, Y.; Martinez, G. J.; Yang, X. O.; Tanaka, S.; Matskevitch, T. D.; Wang, Y. H.; Dong, C. Bcl6 mediates the development of T follicular helper cells. Science 2009, 325, 1001-1005.
60. Yu, D.; Rao, S.; Tsai, L. M.; Lee, S. K.; He, Y.; Sutcliffe, E. L.; Srivastava, M.; Linterman, M.; Zheng, L.; Simpson, N.; et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009, 31, 457-468.
61. Linterman, M. A.; Rigby, R. J.; Wong, R. K.; Yu, D.; Brink, R.; Cannons, J. L.; Schwartzberg, P. L.; Cook, M. C.; Walters, G. D.; Vinuesa, C. G. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 2009, 206, 561-576.
62. Johnston, R. J.; Poholek, A. C.; di Toro, D.; Yusuf, I.; Eto, D.; Barnett, B.; Dent, AL.; Craft, J.; Crotty, S. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009, 325, 1006-1010.
63. Johnston, R. J.; Choi, Y. S.; Diamond, J. A.; Yang, J. A.; Crotty, S. STAT5 is a potent negative regulator of TFH cell differentiation. J. Exp. Med. 2012, 209, 243-250.
64. Laurence, A.; Tato, C. M.; Davidson, T. S.; Kanno, Y.; Chen, Z.; Yao, Z.; Blank, R. B.; Meylan, F.; Siegel, R.; Henninghausen, L.; et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26, 371-381.
65. Malek, T. R.; Castro, I. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 2010, 33, 153-165.
66. + regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 2010, 10, 849-859.
67. Shao, S.; He, F.; Yang, Y.; Yuan, G.; Zhang, M.; Yu, X. Th17 cells in type 1 diabetes. Cell. Immunol. 2012, 280, 16-21.
68. Goudy, K. S.; Johnson, M. C.; Garland, A.; Li, C.; Samulski, R. J.; Wang, B.; Tisch, R. Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J. Immunol. 2011, 186, 3779-3786.
69. Atkinson, M. A.; Leiter, E. H. The NOD mouse model of type 1 diabetes: As good as it gets? Nat. Med. 1999, 5, 601-604.
70. Diaz-de-Durana, Y.; Lau, J.; Knee, D.; Filippi, C.; Londei, M.; McNamara, P.; Nasoff, M.; Dodonatao, M.; Glynne, R.; Herman, A. E. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes. PLoS One 2013, 8, e78483.
71. Bluestone, J. A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464, 1293-1300.
72. Van Belle, T. L.; Coppieters, K. T.; von Herrath, M. G. Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol. Rev. 2011, 91, 79-118.
73. Rabinovitch, A.; Suarez-Pinzon, W. L.; Shapiro, A. M. J.; Rajotte, R. V.; Power, R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002, 51, 638-645.
74. Shin, H. J.; Baker, J.; Leveson-Gower, D. B.; Smith, A. T.; Sega, E. I.; Negrin, R. S. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood 2011, 118, 2342-2350.
75. Piemonti, L.; Maffi, P.; Monti, L.; Lampasona, V.; Perseghin, G.; Magistretti, P.; Secchi, A.; Bonifacio, E. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011, 54, 433-439.
76. Monti, P.; Scirpoli, M.; Maffi, P.; Piemonti, L.; Secchi, A.; Bonifacio, E.; Roncarolo, M. G.; Battaglia, M. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+Foxp3+ regulatory T cells. Diabetes 2008, 57, 2341-2347.
77. Koulmanda, M.; Budo, E.; Bonner-Weir, S.; Qipo, A.; Puthet, P.; Degauque, N.; Shi, H.; Fan, Z.; Flier, J. S.; Auchincloss, H., Jr.; et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc. Natl. Acad. Sci. USA 2007, 104, 13074-13079.
78. Xie, Y.; Wu, M.; Song, M.; Ma, J.; Qin, W.; Jin, Y. A glucocorticoid amplifies IL-2-induced selective expansion of CD4+CD25+FOXP3+ regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation. Acta Biochim. Biophys. Sin. 2009, 41, 781-791.
79. Chen, X.; Oppenheim, J. J.; Winkler-Pickett, T. T.; Ortaldo, J. R.; Howard, O. M. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+ T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 2006, 36, 2139-2149.
80. Yan, X. Q.; Briddell, R.; Hartley, C.; Stoney, G.; Samal, B.; McNiece, I. Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Blood 1994, 84, 795-799.
81. Chen, X.; Murakami, T.; Oppenheim, J. J.; Howard, O. M. Differential response of murine CD4+CD25+ and CD4+CD25-T cells to dexamethasone-induced cell death. Eur. J. Immunol. 2004, 34, 859-869.
82. Churlaud, G.; Jimenez, V.; Ruberte, J.; Zin, M. A.; Fourcade, G.; Gottrand, G.; Casana, E.; Lambrecht, B.; Bellier, B.; Piaggio, E.; et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection vaccination and cancer. Clin. Immunol. 2014, 151, 114-126.
83. Sakaguchi, S. Naturally arising CD4+ regulatory T cells for immunologic self tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22, 531-562.
84. Herold, K. C.; Vignali, D. A.; Cooke, A.; Bluestone, J. A. Type 1 diabetes: Translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 2013, 13, 243-256.
85. Abrams, D.; Levy, Y.; Losso, M. H.; Babiker, A.; Collins, G.; Cooper, D. A; Darbyshire, J.; Emery, S.; INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2009, 361, 1548-1559.
86. Schwartzentruber, D. J.; Lawson, D. H.; Richards, J. M.; Conry, R. M.; Miller, D. M.; Treisman, J.; Gailani, F.; Riley, L.; Conlon, K.; Pockaj, B.; et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364, 2119-2127.
87. + regulatory T cells in cancer patients. Blood 2006, 107, 2409-2414.
88. Josefowicz, S. Z.; Rudensky, A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30, 616-625.
89. Boyman, O.; Purton, J. F.; Surh, C. D.; Sprent, J. Cytokines and T-cell homeostasis. Curr. Opin. Immunol. 2007, 19, 320-326.
90. Valle, A.; Jofra, T.; Stabilini, A.; Atkinson, M.; Roncarolo, M. G.; Battaglia, M. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 2009, 58, 875-881.
91. Yang, S. B.; Lee, H. Y.; Young, D. M.; Tien, A. C.; Rowson-Baldwin, A.; Shu, Y. Y.; Jan, Y. N.; Jan, L. Y. Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity. J. Mol. Med. 2012, 90, 575-585.
92. De Paz, B.; Alper-Lopez, M.; Ballina-Garcia, F. J.; Prado, C.; Mozo, L.; Gutierrez, C.; Suarez, A. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis-association with clinical response to glucocorticoids. J. Rheumatol. 2010, 37, 503-511.
93. De Paz, B.; Alper-Lopez, M.; Ballina-Garcia, F. J.; Prado, C.; Gutierrez, C.; Suarez, A. Cytokines and regulatory T cells in rheumatoid arthritis and their relationship with response to corticosteroids. J. Rheumatol. 2010, 37, 2502-2510.
94. Margolin, K.; Atkins, M. B.; Dutcher, J. P.; Ernstoff, M. S.; Smith, J. W., 2nd; Clark, J. I.; Baar, J.; Sosman, J.; Weber, J.; Brunetti, J.; et al. Phase I trial of BAY 50-4798, an interlukin-2-specific agonist in advanced melanoma and renal cancer. Clin. Cancer Res. 2007, 13, 3312-3319.
95. Pretto, F.; Elia, G.; Castioni, N.; Neri, D. Preclinical evaluation of IL-2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol. Immunother. 2014, 63, 901-910.
96. Liao, W.; Lin, J. X.; Leonard, W. J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38, 13-25.